Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative

Sickle cell disease (SCD) is an inherited blood disorder that affects about 100,000 people in the U.S., primarily Blacks/African-Americans. A multitude of complications negatively impacts quality of life. Hydroxyurea has been FDA approved since 1998 as a disease-modifying therapy for SCD, but is und...

Descripción completa

Detalles Bibliográficos
Autores principales: Treadwell, Marsha J., Du, Lisa, Bhasin, Neha, Marsh, Anne M., Wun, Theodore, Bender, M. A., Wong, Trisha E., Crook, Nicole, Chung, Jong H., Norman, Shannon, Camilo, Nicolas, Cavazos, Judith, Nugent, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461276/
https://www.ncbi.nlm.nih.gov/pubmed/36092883
http://dx.doi.org/10.3389/fgene.2022.921432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461276/
https://www.ncbi.nlm.nih.gov/pubmed/36092883
http://dx.doi.org/10.3389/fgene.2022.921432

Ejemplares similares